These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27224915)

  • 1. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA XIST: a novel independent prognostic biomarker for patients with ABC-DLBCL receiving R-CHOP treatment.
    Li HB; Wang D; Zhang Y; Shen D; Che YQ
    Carcinogenesis; 2024 Jul; 45(7):500-509. PubMed ID: 38426786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
    Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
    Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
    Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
    Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms.
    Yu H; Peng S; Han S; Chen X; Lyu Q; Lei T
    Biomed Res Int; 2021; 2021():5514726. PubMed ID: 34250086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
    Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
    Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma.
    Hui X; Li L; Xiong W; Liu Y; Li H; Zhang H; Zhao S; Zhang Y
    Clin Exp Med; 2024 Apr; 24(1):89. PubMed ID: 38683255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
    Lu X; Chen J; Sasmono RT; Hsi ED; Sarosiek KA; Tiganis T; Lossos IS
    Mol Cell Biol; 2007 Mar; 27(6):2166-79. PubMed ID: 17210636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis.
    Jespersen DS; Schönherz AA; Due H; Bøgsted M; Sondergaard TE; Dybkær K
    Sci Rep; 2019 Jan; 9(1):335. PubMed ID: 30674940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release.
    Hussain AR; Uddin S; Ahmed M; Al-Dayel F; Bavi PP; Al-Kuraya KS
    PLoS One; 2013; 8(3):e60540. PubMed ID: 23555990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in biology, diagnosis and treatment of DLBCL.
    Shi Y; Xu Y; Shen H; Jin J; Tong H; Xie W
    Ann Hematol; 2024 Jul; ():. PubMed ID: 39017945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
    Tabari E; Lovejoy AF; Lin H; Bolen CR; Lor Saelee S; Lefkowitz JP; Kurtz DM; Bottos A; Nielsen TG; Parreira JM; Luong KT
    Leuk Lymphoma; 2024 May; 65(5):618-628. PubMed ID: 38337191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.
    Felce SL; Anderson AP; Maguire S; Gascoyne DM; Armstrong RN; Wong KK; Li D; Banham AH
    Front Oncol; 2020; 10():448. PubMed ID: 32309216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumoural Pellino-1 expression and Pellino-1-expressive cytotoxic T-cells are associated with poor prognosis in diffuse large B-cell lymphoma.
    Shin SJ; Ko J; Hwang HS; Huh J; Lee CW; Lee JK; Go H
    Pathology; 2024 Apr; 56(3):374-381. PubMed ID: 38296676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
    Schmitt A; Grimm M; Kreienkamp N; Junge H; Labisch J; Schuhknecht L; Schönfeld C; Görsch E; Tibello A; Menck K; Bleckmann A; Lengerke C; Rosenbauer F; Grau M; Zampieri M; Schulze-Osthoff K; Klener P; Dolnikova A; Lenz G; Hailfinger S
    Blood; 2023 Sep; 142(13):1143-1155. PubMed ID: 37294920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
    Xu-Monette ZY; Li Y; Snyder T; Yu T; Lu T; Tzankov A; Visco C; Bhagat G; Qian W; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Wang Y; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Fan X; van Krieken JH; Piris MA; Winter JN; Au Q; Kirsch I; Zhang M; Shaughnessy J; Xu B; Young KH
    Clin Cancer Res; 2023 Dec; 29(23):4808-4821. PubMed ID: 37728879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
    Choi J; Ceribelli M; Phelan JD; Häupl B; Huang DW; Wright GW; Hsiao T; Morris V; Ciccarese F; Wang B; Corcoran S; Scheich S; Yu X; Xu W; Yang Y; Zhao H; Zhou J; Zhang G; Muppidi J; Inghirami GG; Oellerich T; Wilson WH; Thomas CJ; Staudt LM
    Cancer Cell; 2024 May; 42(5):833-849.e12. PubMed ID: 38701792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL).
    Wang Y; Tsukamoto Y; Hori M; Iha H
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.